Patritumab Deruxtecan for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 24 Aug 2017: Trial registered, NCT03260491
  2. 30 Oct 2017: Trial started, NCT03260491
  3. 21 Dec 2020: Trial registered, NCT04676477
  4. 11 Jun 2021: Trial started, NCT04676477

The trials

NCT03260491: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

State
Under way
Phase
Phase 1
People
312 taking part
Started
30 Oct 2017
Primary completion
1 Dec 2025
Arms
Dose Escalation: Cohort 1, 3.2 mg/kg, Dose Escalation: Cohort 2, 4.8 mg/kg, Dose Escalation: Cohort 3, 5.6 mg/kg, Dose Escalation: Cohort 4, 6.4 mg/kg, Dose Expansion: Cohort 1, EGFR mutant, Dose Expansion: Cohort 2, EGFR wild-type, Dose Expansion: Cohort 3a, EGFR mutant, Dose Expansion: Cohort 3b, EGFR mutant, Dose Expansion: Cohort 4, EGFR mutant, Dose Expansion: Cohort 5, KRAS-G12C mutant NSCLC
Results
None posted
  1. 24 Aug 2017: Trial registered
  2. 30 Oct 2017: Trial started

NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

State
Under way
Phase
Phase 1
People
246 taking part
Started
11 Jun 2021
Primary completion
31 Jan 2025
Arms
Second-line Dose Expansion: HER3-DXd
Results
None posted
  1. 21 Dec 2020: Trial registered
  2. 11 Jun 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as HER3-DXd, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP), HER3-DXd (FL-DP), Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.